- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659564
Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study (DAYSPRING)
May 28, 2021 updated by: Koya Medical, Inc.
An open-label study to clinically assess a novel wearable advanced compression technology (Dayspring™) undertaken to determine if potential barriers to lymphedema self-care were effectively addressed. The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system. The following endpoints are examined:
- Improvement in QoL in subject with upper-extremity edema after 28 days as measured by the LYMQOL disease-specific validated assessment tool.
- Arm volume maintenance or improvement as measured prior to and after 28 days of device use.
- Safety as assessed by reported adverse events
- Patient satisfaction as measured by visual analog scale (VAS) and survey at the end of the study; and
- Adherence to therapy as measured with a smart phone app.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Altos, California, United States, 94024
- PT works
-
Morgan Hill, California, United States, 95037
- Ginger-K Lymphedema & Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females ≥ 18 years of age
- Willing to sign the informed consent and deemed capable of following the study protocol
- Subjects must have a diagnosis of primary or secondary unilateral or bilateral upper extremity edema
Exclusion Criteria:
- Individuals with a history or presence of a systemic disorder or condition that could place the patient at increased risk from sequential compression therapy
- Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent
- Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)
- Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer
- Diagnosis of Acute infection (in the last two weeks)
- Diagnosis of acute thrombophlebitis (in last 2 months)
- Diagnosis of peripheral arterial disease (PAD): PAD is defined as an Ankle Brachial Index (ABI), of 0.7 or lower
- Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
- Diagnosis of pulmonary edema
- Diagnosis of congestive heart failure (uncontrolled)
- Diagnosis of chronic kidney disease
- Diagnosis of epilepsy
- Patients with poorly controlled asthma
- Any condition where increased venous and lymphatic return is undesirable
- Women who are pregnant, planning a pregnancy or nursing at study entry
- Participation in any clinical trial of an investigational substance or device during the past 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Breast-cancer related lymphedema (BCRL)
|
The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LYMQOL (LYMphedema Quality of Life)
Time Frame: 28 days
|
The Lymphedema Quality of Life Questionnaire (LYMQOL), a validated disease-specific QoL tool, was also administered at baseline and at day 28.
Overall QoL is scored on a single item by the patient on a scale of 1-10.
|
28 days
|
Arm Volume Maintenance or Improvement
Time Frame: 28 days
|
Limb volume measurement was performed by using a calibrated tape measure to measure circumference from the wrist and the ulnar styloid process and at 4cm increments to the axilla.
Measurements were taken for both upper extremities.
If both extremities exhibited edema, a study arm was designated for treatment.
Measurements were taken by the same investigator throughout the study.
Volume was calculated based on cylindrical segment analysis.
|
28 days
|
Safety/AEs
Time Frame: 28 days
|
As assessed by reported adverse events
|
28 days
|
Therapy adherence tracking
Time Frame: 28 days
|
Therapy adherence tracked via the mobile app linked to the Dayspring™ device.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient survey
Time Frame: 28 days
|
A visual analog scale (VAS) and study survey were administered at the end of the study to measure patient satisfaction (day 28).
The six-item questionnaire was used to document the time of day the device was used, if daily activities were supported during use, function, and symptoms.
All were measured on a scale from 1-5.
The VAS was administered to previous users of pneumatic compression devices to assess preference and likelihood to recommend to others with lymphedema.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stanley G Rockson, MD, Medical Advisor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 5, 2020
Primary Completion (Actual)
May 28, 2021
Study Completion (Actual)
May 28, 2021
Study Registration Dates
First Submitted
November 10, 2020
First Submitted That Met QC Criteria
December 2, 2020
First Posted (Actual)
December 9, 2020
Study Record Updates
Last Update Posted (Actual)
June 1, 2021
Last Update Submitted That Met QC Criteria
May 28, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KCT001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
Clinical Trials on User of Dayspring device
-
Léman Micro Devices SAUnknownClinical Accuracy of Vital Sign Pressure Sensor
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema of Upper Arm | Lymphedema, Breast CancerUnited States
-
Koya Medical, Inc.CompletedLymphedema | Venous Insufficiency | Chronic Venous Insufficiency | Lymphedema, Lower Limb | Lymphedema of LegUnited States
-
Healthy.io Ltd.CompletedUrine Detectable Acute and Chronic DiseasesUnited States
-
Two Pi Signalprocessing Applications GmbHCompletedMild to Moderate Sensorineural Hearing LossNetherlands
-
Fisher and Paykel HealthcareCompletedObstructive Sleep Apnea | Sleep Disordered BreathingNew Zealand
-
Vestre Viken Hospital TrustUniversity of Oslo; Oslo University Hospital; University of Bergen; Haukeland University...Recruiting
-
University Hospital, GhentRecruitingHyperammonemic EncephalopathyBelgium
-
University of California, San FranciscoTerminatedPulmonary Disease, Chronic Obstructive | Pulmonary Diseases, ObstructiveUnited States